Olopatadine Hydrochloride Ophthalmic Solution 0.2%

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Allergic Conjunctivitis

Drug Information

Target Indication

Allergic Conjunctivitis

Clinical Trial

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA5/16/2002

Opatanol

Treatment of ocular signs and symptoms of seasonal allergic conjunctivitis.

Drug Science

Mechanism of action & safety profile

Developer

ALC

Alcon Research

Related Pipeline

Acute Otitis Media

Endogenous Anterior Uveitis

Allergic Conjunctivitis

Allergic Conjunctivitis

Glaucoma, Open-angle